Pancreatic Cancer Research

ResearcherFondazione Poliambulanza Istituto OspedalieroActive in the last 2 years

Alberto Zaniboni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2140-7040; OpenAlex author ID A5045260424. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 5 papers

Papers 21

  1. Targeting RAS in pancreatic cancer. Last author DOI 10.1002/cncr.70640↗
  2. Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes. Last author DOI 10.1016/j.ctrv.2026.103170↗
  3. Fostering human dignity during chemotherapy: An explorative study on Dignity Therapy in advanced gastric and pancreatic cancer. Last author DOI 10.1017/s1478951526103472↗
  4. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  5. Incidental detection of PDAC via 18F-PSMA PET/CT in a patient with recurrent prostate cancer. A case report. Last author DOI 10.3389/fnume.2026.1767321↗
  6. Depression as a Prodromal Symptom of Pancreatic Cancer: A Narrative Review. Last author DOI 10.3390/cancers18010016↗
  7. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  8. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  9. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomi… Co-author DOI 10.1016/j.ejca.2021.02.023↗
  10. Pancreatic adenocarcinoma: Beyond first line, where are we? Last author DOI 10.3748/wjg.v27.i17.1847↗
  11. Weight loss in pancreatic cancer: A missing criterion of resecability. First author DOI 10.1016/j.pan.2020.04.022↗
  12. Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. First author DOI 10.3390/cancers11040550↗
  13. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current L… First author DOI 10.3390/jcm8111922↗
  14. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  15. Immunotherapy for pancreatic cancer: present and future. First author DOI 10.2217/imt-2016-0142↗
  16. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2016.271↗
  17. Pancreatic Cancer: Promises and Failures of Target Therapies. Last author DOI 10.2174/1574887110666150930122720↗
  18. Pancreatic cancer: New hopes after first line treatment. Last author DOI 10.4251/wjgo.v8.i9.682↗
  19. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Co-author DOI 10.18632/oncotarget.5197↗
  20. Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis. Last author DOI 10.2174/1574887110666150417115303↗
  21. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Co-author DOI 10.1007/s00280-012-1875-1↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fausto Petrelli · 3 shared papers, 2019–2026 · strength 0.89
  2. Lorenzo Dottorini · 2 shared papers, 2026 · strength 0.79
  3. Ester Oneda · 3 shared papers, 2019–2026 · strength 0.77
  4. Sara Cherri · 3 shared papers, 2020–2026 · strength 0.75
  5. Federica Andreis · 2 shared papers, 2025–2026 · strength 0.71
  6. Chiara Deori · 2 shared papers, 2025–2026 · strength 0.71
  7. Letizia Procaccio · 3 shared papers, 2023–2026 · strength 0.48
  8. Elisa Giommoni · 3 shared papers, 2023–2026 · strength 0.48
  9. Sara Lonardi · 3 shared papers, 2023–2026 · strength 0.48
  10. Ferdinando De Vita · 3 shared papers, 2023–2026 · strength 0.48
  11. Francesca Bergamo · 3 shared papers, 2023–2026 · strength 0.48
  12. Guido Giordano · 3 shared papers, 2023–2026 · strength 0.48
  13. Davide Melisi · 3 shared papers, 2023–2026 · strength 0.48
  14. Giordano Savelli · 3 shared papers, 2015–2026 · strength 0.48
  15. Roberto Bianco · 3 shared papers, 2021–2026 · strength 0.44
  16. Gianluca Tomasello · 2 shared papers, 2019–2026 · strength 0.39
  17. Michele Ghidini · 2 shared papers, 2019–2026 · strength 0.39
  18. Mario Scartozzi · 3 shared papers, 2015–2026 · strength 0.37
  19. Matteo Landriscina · 2 shared papers, 2024–2026 · strength 0.35
  20. Giampaolo Tortora · 2 shared papers, 2024–2026 · strength 0.35
  21. Enrico Vasile · 2 shared papers, 2024–2026 · strength 0.35
  22. Francesca Aroldi · 4 shared papers, 2015–2017 · strength 0.35
  23. Andrea Pretta · 2 shared papers, 2023–2026 · strength 0.33
  24. Simona Casalino · 2 shared papers, 2023–2026 · strength 0.33
  25. Vanja Vaccaro · 2 shared papers, 2023–2024 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.